Variant spectrum of von Hippel–Lindau disease and its genomic heterogeneity in Japan
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Von Hippel–Lindau (VHL) disease is an autosomal dominant, inherited syndrome with variants in the VHL gene, causing predisposition to multi-organ neoplasms with vessel abnormality. Germline variants in VHL can be detected in 80–90% of patients clinically diagnosed with VHL disease. Here, we summarize the results of genetic tests for 206 Japanese VHL families, and elucidate the molecular mechanisms of VHL disease, especially in variant-negative unsolved cases. Of the 206 families, genetic diagnosis was positive in 175 families (85%), including 134 families (65%) diagnosed by exon sequencing (15 novel variants) and 41 (20%) diagnosed by multiplex ligation-dependent probe amplification (MLPA) (one novel variant). The deleterious variants were significantly enriched in VHL disease Type 1. Interestingly, five synonymous or non-synonymous variants within exon 2 caused exon 2 skipping, which is the first report of exon 2 skipping caused by several missense variants. Whole genome and target deep sequencing analysis were performed for 22 unsolved cases with no variant identified and found three cases with VHL mosaicism (variant allele frequency: 2.5–22%), one with mobile element insertion in the VHL promoter region, and two with a pathogenic variant of BAP1 or SDHB. The variants associated with VHL disease are heterogeneous, and for more accuracy of the genetic diagnosis of VHL disease, comprehensive genome and DNA/RNA analyses are required to detect VHL mosaicism, complicated structure variants and other related gene variants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · cited 6×
“Regarding the genotype–phenotype correlation of VHL disease, Type 1 is characterized by large deletions, and truncating variants, associated with VHL instability and high HIF activity (21–23).”
InfluentialTargeting renal cell carcinoma with a HIF-2 antagonist
Chen, W., Hill, H., Christie, A., Kim, M. S., Holloman, E., Pavia-Jimenez, A., Homayoun, F., Ma, Y., Patel, N., Yell, P., et al. (2016) · Nature · doi:10.1038/nature19796 · Cited by 709
On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models
Cho, H., Du, X., Rizzi, J. P., Liberzon, E., Chakraborty, A. A., Gao, W., Carvo, I., Signoretti, S., Bruick, R. K., Josey, J. A., et al. (2016) · Nature · doi:10.1038/nature19795 · Cited by 451
A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma
Wallace, E. M., Rizzi, J. P., Han, G., Wehn, P. M., Cao, Z., Du, X., Cheng, T., Czerwinski, R. M., Dixon, D. D., Goggin, B. S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0473 · Cited by 336
Research works printed but not linked: 25
- Lonser, 2003, von Hippel-Lindau disease, Lancet, 361, 2059, 10.1016/S0140-6736(03)13643-4 · DOI · Paper page
- Maher, 1991, Von Hippel-Lindau disease: a genetic study, J. Med. Genet., 28, 443, 10.1136/jmg.28.7.443 · DOI · Paper page
- Nordstrom-O'Brien, 2010, Genetic analysis of von Hippel-Lindau disease, Hum. Mutat., 31, 521
- Andreou, 2022, Elongin C (ELOC/TCEB1)-associated von Hippel-Lindau disease, Hum. Mol. Genet., 31, 2728, 10.1093/hmg/ddac066 · DOI
- Jaakkola, 2001, Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2 regulated prolyl hydroxylation, Science, 292, 468, 10.1126/science.1059796 · DOI · Paper page
- Pouysségur, 2006, Hypoxia signalling in cancer and approaches to enforce tumour regression, Nature, 441, 437, 10.1038/nature04871 · DOI · Paper page
- Bradley, 1999, Two distinct phenotypes caused by two different missense mutations in the same codon of the VHL gene, Am. J. Med. Genet., 87, 163, 10.1002/(SICI)1096-8628(19991119)87:2<163::AID-AJMG7>3.0.CO;2-A · doi:10.1002/(sici)1096-8628(19991119)87:2<163::aid-ajmg7>3.0.co;2-a
- Liu, 2020, Case report: a synonymous VHL mutation (c.414A > G, p.Pro138Pro) causes pathogenic familial hemangioblastoma through dysregulated splicing, BMC Med Genet., 21, 42, 10.1186/s12881-020-0976-7 · DOI
- Flores, 2019, A synonymous VHL variant in exon 2 confers susceptibility to familial pheochromocytoma and von Hippel-Lindau disease, J. Clin. Endocrinol. Metab., 104, 3826, 10.1210/jc.2019-00235 · DOI
- Kojima, 2022, Mobile elements in human population-specific genome and phenotype divergence, bioRxiv
- Renbaum, 1996, Isolation and characterization of the full-length 3′ untranslated region of the human von Hippel-Lindau tumor suppressor gene, Hum. Genet., 98, 666, 10.1007/s004390050281 · DOI
- Iliopoulos, 1995, Tumour suppression by the human von Hippel-Lindau gene product, Nat. Med., 1, 822, 10.1038/nm0895-822 · DOI · Paper page
- Schoenfeld, 1998, A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor, Proc. Natl. Acad. Sci. USA., 95, 8817, 10.1073/pnas.95.15.8817 · DOI · Paper page
- Hascoet, 2017, The pVHL172 isoform is not a tumor suppressor and up-regulates a subset of pro-tumorigenic genes including TGFB1 and MMP13, Oncotarget, 8, 75989, 10.18632/oncotarget.18376 · DOI
- Zbar, 1996, Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan, Hum. Mutat., 8, 348, 10.1002/(SICI)1098-1004(1996)8:4<348::AID-HUMU8>3.0.CO;2-3 · DOI · Paper page
- Yoshida, 2000, Germ-line mutation analysis in patients with von Hippel-Lindau disease in Japan: an extended study of 77 families, Jpn. J. Cancer Res., 91, 204, 10.1111/j.1349-7006.2000.tb00933.x · DOI
- Chou, 2013, von Hippel-Lindau syndrome, Front. Horm. Res., 41, 30, 10.1159/000345668 · DOI
- Aronow, 2019, VON HIPPEL-LINDAU DISEASE: update on pathogenesis and systemic aspects, Retina, 39, 2243, 10.1097/IAE.0000000000002555 · DOI
- Maher, 2019, von Hippel-Lindau disease: an update, Curr. Genet. Med. Rep., 7, 227, 10.1007/s40142-019-00180-9 · DOI
- Sgambati, 2000, Mosaicism in von Hippel-Lindau disease: lessons from kindreds with germline mutations identified in offspring with mosaic parents, Am. J. Hum. Genet., 66, 84, 10.1086/302726 · DOI · Paper page
- Coppin, 2019, Optimization of next-generation sequencing technologies for von Hippel Lindau (VHL) mosaic mutation detection and development of confirmation methods, J Mol Diagn., 21, 462, 10.1016/j.jmoldx.2019.01.005 · doi:10.1016/j.jmoldx.2019.01.005
- Oldfield, 2022, VHL mosaicism: the added value of multi-tissue analysis, NPJ Genom Med., 7, 21, 10.1038/s41525-022-00291-3 · doi:10.1038/s41525-022-00291-3
- Sekine, 2022, Different risk genes contribute to clear cell and non-clear cell renal cell carcinoma in 1532 Japanese patients and 5996 controls, Hum. Mol. Genet., 31, 1962
- Lenglet, 2018, Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease, Blood, 132, 469, 10.1182/blood-2018-03-838235 · DOI
- Buffet, 2020, Germline mutations in the new E1' cryptic exon of the VHL gene in patients with tumours of von Hippel-Lindau disease spectrum or with paraganglioma, J. Med. Genet., 57, 752, 10.1136/jmedgenet-2019-106519 · DOI
Metadata
- Authors
- Tamura, K., Kanazashi, Y., Kawada, C., Sekine, Y., Maejima, K., Ashida, S., Karashima, T., Kojima, S., Parrish, N. F., Kosugi, S., Terao, C., Sasagawa, S., Fujita, M., Johnson, T. A., Momozawa, Y., Inoue, K., Shuin, T., & Nakagawa, H.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-03-11
- Volume
- 32
- Issue
- 12
- Pages
- 2046-2054
- ISSN
- 0964-6906
- 1460-2083
- Cited by
- 14
- References
- 4
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.